If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The NHS specifically warns patients taking selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

According to the National Capital Poison Center, a not-for-profit poison control organization, at least 85 drugs—including ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...

The selective serotonin reuptake inhibitor sertraline is often among the preferred antidepressants to take when breastfeeding ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...